白细胞介素-22在心血管疾病中的作用

doi:10.19586/j.2095-2341.2024.0030

生物技术进展 ›› 2024, Vol. 14 ›› Issue (5): 820-824.DOI: 10.19586/j.2095-2341.2024.0030

• 进展评述 • 上一篇

白细胞介素-22在心血管疾病中的作用

肖玲玲¹^,²^,³(), 包明威¹^,²^,³()

^1.武汉大学人民医院心血管内科，武汉 430060
^2.武汉大学心血管病研究所，武汉 430060
^3.心血管病湖北省重点实验室，武汉 430060

收稿日期:2024-02-24 接受日期:2024-04-08 出版日期:2024-09-25 发布日期:2024-10-22
通讯作者: 包明威
作者简介:肖玲玲 E-mail：13277097138@163.com；
基金资助:
国家自然科学基金项目(81970438)

Roles of Interleukin-22 in Cardiovascular Disease

Lingling XIAO¹^,²^,³(), Mingwei BAO¹^,²^,³()

^1.Department of Cardiology，Renmin Hospital of Wuhan University，Wuhan 430060，China
^2.Cardiovascular Research Institute of Wuhan University，Wuhan 430060，China
^3.Hubei Key Laboratory of Cardiology，Wuhan 430060，China

Received:2024-02-24 Accepted:2024-04-08 Online:2024-09-25 Published:2024-10-22
Contact: Mingwei BAO

摘要/Abstract

摘要：

白细胞介素22（interleukin-22，IL-22）属于IL-10家族，主要由T辅助细胞Th1、Th17、Th22、天然淋巴细胞（innate lymphoid cells，ILCs）、CD4⁺T和CD8⁺T细胞等多种淋巴细胞产生，是具有特异性作用的细胞效应因子。随着研究的深入，IL-22与多种代谢性疾病和心血管疾病的关系逐步得到揭示，IL-22信号在其中可能具有双重作用。就IL-22的来源、功能、调节以及IL-22信号在心血管疾病中的作用等方面的研究进展作出综述，以期对未来心血管疾病的临床治疗提供方案。

关键词: 白细胞介素-22, 心血管疾病, 代谢

Abstract:

Interleukin-22 （IL-22） belongs to the IL-10 family and is mainly produced by T helper cells Th1， Th17， Th22， innate lymphoid cells （ILCs）， CD4⁺T and CD8⁺T cells and other lymphocytes. They are cellular effectors with specific effects. With the progress of research， the correlation of IL-22 with a variety of metabolic diseases and cardiovascular diseases has been gradually revealed， and IL-22 signaling may have a dual role in them. This article reviewed the source， function， regulation of IL-22 and the role of IL-22 signaling in cardiovascular diseases， in order to provide a plan for the clinical treatment of cardiovascular diseases in the future.

Key words: interleukin-22, cardiovascular diseases, metabolism

中图分类号:

R714.252

肖玲玲, 包明威. 白细胞介素-22在心血管疾病中的作用[J]. 生物技术进展, 2024, 14(5): 820-824.

Lingling XIAO, Mingwei BAO. Roles of Interleukin-22 in Cardiovascular Disease[J]. Current Biotechnology, 2024, 14(5): 820-824.

参考文献 34

1	DAMLUJI A A, ALFARAIDHY M, ALHAJRI N, et al.. Sarcopenia and cardiovascular diseases[J]. Circulation, 2023, 147(20): 1534-1553.
2	ZHENG Y, LI T. Interleukin-22, a potent target for treatment of non-autoimmune diseases[J]. Hum. Vaccin. Immunother., 2018, 14(12): 2811-2819.
3	DOULABI H, RASTIN M, SHABAHANGH H, et al.. Analysis of Th22, Th17 and CD4⁺ cells co-producing IL-17/IL-22 at different stages of human colon cancer[J]. Biomed. Pharmacother., 2018, 103: 1101-1106.
4	ZERBINI A, MURATORE F, BOIARDI L, et al.. Increased expression of interleukin-22 in patients with giant cell arteritis[J]. Rheumatology (Oxford), 2018, 57(1): 64-72.
5	OUYANG W, O'GARRA A. IL-10 family cytokines IL-10 and IL-22: from basic science to clinical translation[J]. Immunity, 2019, 50(4): 871-891.
6	YAMAMOTO M, YASUKAWA H, TAKAHASHI J, et al.. Endogenous interleukin-22 prevents cardiac rupture after myocardial infarction in mice[J/OL]. PLoS One, 2023, 18(6): e0286907[2023-09-18]. .
7	HE W, ZHOU L, XU K, et al.. Immunopathogenesis and immunomodulatory therapy for myocarditis[J]. Sci. China Life Sci., 2023, 66(9): 2112-2137.
8	SAHU U, BISWAS D, PRAJAPATI V K, et al.. Interleukin-17-a multifaceted cytokine in viral infections[J]. J. Cell. Physiol., 2021, 236(12): 8000-8019.
9	KWONG J C, SCHWARTZ K L, CAMPITELLI M A. Acute myocardial infarction after laboratory-confirmed influenza infection[J]. N. Engl. J. Med., 2018, 378(26): 2540-2541.
10	TANG T T, LI Y Y, LI J J, et al.. Liver-heart crosstalk controls IL-22 activity in cardiac protection after myocardial infarction[J]. Theranostics, 2018, 8(16): 4552-4562.
11	BENNETT M R, SINHA S, OWENS G K. Vascular smooth muscle cells in atherosclerosis[J]. Circ. Res., 2016, 118(4): 692-702.
12	KUBOTA A, SUTO A, SUGA K, et al.. Inhibition of Interleukin-21 prolongs the survival through the promotion of wound healing after myocardial infarction[J]. J. Mol. Cell. Cardiol., 2021, 159: 48-61.
13	JONSSON A L, BÄCKHED F. Role of gut microbiota in atherosclerosis[J]. Nat. Rev. Cardiol., 2017, 14(2): 79-87.
14	POTHINENI N V K, SUBRAMANY S, KURIAKOSE K, et al.. Infections, atherosclerosis, and coronary heart disease[J]. Eur. Heart J., 2017, 38(43): 3195-3201.
15	FATKHULLINA A R, PESHKOVA I O, DZUTSEV A, et al.. An interleukin-23-interleukin-22 axis regulates intestinal microbial homeostasis to protect from diet-induced atherosclerosis[J]. Immunity, 2018, 49(5): 943-957.
16	CARRERAS A, BÄCKHED F. 23, 22 calling the microbiota to control atherosclerosis[J]. Immunity, 2018, 49(5): 788-790.
17	QIU Y, XU S, CHEN X, et al.. NAD⁺ exhaustion by CD38 upregulation contributes to blood pressure elevation and vascular damage in hypertension[J/OL]. Signal Transduct. Target. Ther., 2023, 8(1): 353[2023-09-18]. .
18	RATTIK S, HULTMAN K, RAUCH U, et al.. IL-22 affects smooth muscle cell phenotype and plaque formation in apolipoprotein E knockout mice[J]. Atherosclerosis, 2015, 242(2): 506-514.
19	CHEN S, LI X, WANG Y, et al.. Ginsenoside Rb1 attenuates intestinal ischemia/reperfusion-induced inflammation and oxidative stress via activation of the PI3K/Akt/Nrf2 signaling pathway[J]. Mol. Med. Rep., 2019, 19(5): 3633-3641.
20	CHELLAN B, YAN L, SONTAG T J, et al.. IL-22 is induced by S100/calgranulin and impairs cholesterol efflux in macrophages by downregulating ABCG1[J]. J. Lipid Res., 2014, 55(3): 443-454.
21	PADMANABHAN S, JOE B. Towards precision medicine for hypertension: a review of genomic, epigenomic, and microbiomic effects on blood pressure in experimental rat models and humans[J]. Physiol. Rev., 2017, 97(4): 1469-1528.
22	RODRIGUEZ-ITURBE B, PONS H, JOHNSON R J. Role of the immune system in hypertension[J]. Physiol. Rev., 2017, 97(3): 1127-1164.
23	LI R, ZHU L, WU M, et al.. Serum pharmacochemistry combined with network pharmacology-based mechanism prediction and pharmacological validation of Zhenwu Decoction on alleviating isoprenaline-induced heart failure injury in rats[J]. ACS Omega, 2023, 8(40): 37233-37247.
24	GARTZONIKAS I K, NAKA K K, ANASTASAKIS A. Current and emerging perspectives on pathophysiology, diagnosis, and management of hypertrophic cardiomyopathy[J]. Hellenic J. Cardiol., 2023, 70: 65-74.
25	DVIR D, LEON M B, ABDEL-WAHAB M, et al.. First-in-human dedicated leaflet splitting device for prevention of coronary obstruction in transcatheter aortic valve replacement[J]. JACC Cardiovasc. Interv., 2023, 16(1): 94-102.
26	JAPP A G, GULATI A, COOK S A, et al.. The diagnosis and evaluation of dilated cardiomyopathy[J]. J. Am. Coll. Cardiol., 2016, 67(25): 2996-3010.
27	SHEN J, FANG Y, ZHU H, et al.. Plasma interleukin-22 levels are associated with prediabetes and type 2 diabetes in the Han Chinese population[J]. J. Diabetes Investig., 2018, 9(1): 33-38.
28	HU M, LIN H, YANG L, et al.. Interleukin-22 restored mitochondrial damage and impaired glucose-stimulated insulin secretion through down-regulation of uncoupling protein-2 in INS-1 cells[J]. J. Biochem., 2017, 161(5): 433-439.
29	HARTMANN P, DUAN Y, MIYAMOTO Y, et al.. Colesevelam ameliorates non-alcoholic steatohepatitis and obesity in mice[J]. Hepatol. Int., 2022, 16(2): 359-370.
30	NAPPI F, AVTAAR SINGH S S. Distinctive signs of disease as deterrents for the endothelial function: a systematic review[J/OL]. Metabolites, 2023, 13(3): 430[2023-09-18]. .
31	JAACKS L M, VANDEVIJVERE S, PAN A, et al.. The obesity transition: stages of the global epidemic[J]. 2019, 7(3): 231-240.
32	BOSSONE E, GORLA R, LABOUNTY T M, et al.. Presenting systolic blood pressure and outcomes in patients with acute aortic dissection[J]. J. Am. Coll. Cardiol., 2018, 71(13): 1432-1440.
33	EVANGELISTA A, ISSELBACHER E M, BOSSONE E, et al.. Insights from the international registry of acute aortic dissection: a 20-year experience of collaborative clinical research[J]. Circulation, 2018, 137(17): 1846-1860.
34	YE J, WANG M, JIANG H, et al.. Increased levels of interleukin-22 in thoracic aorta and plasma from patients with acute thoracic aortic dissection[J]. Clin. Chim. Acta, 2018, 486: 395-401.

[1]	季洁, 孔雅茹, 王珊, 邰隽. 基于气相色谱-质谱联用技术检测阻塞性睡眠呼吸暂停儿童血浆代谢变化的研究[J]. 生物技术进展, 2024, 14(4): 657-667.
[2]	邹凯. 植物毛状根研究及应用[J]. 生物技术进展, 2024, 14(3): 341-348.
[3]	席照青, 包明威. 巨噬细胞糖脂代谢重编程在非酒精性脂肪肝中的研究进展[J]. 生物技术进展, 2024, 14(3): 399-405.
[4]	李一凡, 冯伟伟, 茆广华, 赵婷, 陈瑶, 罗梦娜, 耿鑫, 吴朝琼, 仰榴青, 吴向阳. 杀螟硫磷暴露对大鼠肝细胞的代谢毒性及机制研究[J]. 生物技术进展, 2024, 14(3): 459-465.
[5]	王立雯, 王江坤, 王冰冰, 徐剑宏, 史建荣, 刘馨. 镰刀菌毒素在植物与病原菌互作过程中的作用[J]. 生物技术进展, 2024, 14(2): 182-188.
[6]	陈巧莉, 黄杰, 陈森瑜, 潘少婷, 唐灵芝, 洪璇. 海洋链霉菌次级代谢产物研究进展[J]. 生物技术进展, 2023, 13(6): 844-852.
[7]	代地林, 吴园, 包明威. 单胺氧化酶A介导的活性氧簇在心血管疾病中的作用[J]. 生物技术进展, 2023, 13(4): 542-546.
[8]	熊茂兰, 蔚思言, 罗军涛, 韩兵社, 张俊芳. 敲除hdac11基因对斑马鱼脂代谢的影响[J]. 生物技术进展, 2023, 13(4): 588-595.
[9]	白亮, 黄鹤, 王苹. 合成生物学在治疗代谢性疾病中的研究进展[J]. 生物技术进展, 2023, 13(3): 383-389.
[10]	赵俊魁, 卢永忠. 蓝藻细胞工厂的研究进展[J]. 生物技术进展, 2023, 13(2): 174-180.
[11]	宋开南, 谢李楠, 徐玉泉. 真菌除草活性次级代谢产物研究进展[J]. 生物技术进展, 2023, 13(2): 181-194.
[12]	杨洋, 王凤林, 刘德, 罗园园, 朱建华. CRISPR⁃Cas9技术在植物次生代谢物生产中的研究进展[J]. 生物技术进展, 2022, 12(6): 806-816.
[13]	刘梓嘉, 姜雪, 仪杨, 王濛, 马晨, 宋怡菲, 谢飞. 氢气与肠道菌群的关系研究进展[J]. 生物技术进展, 2022, 12(6): 847-852.
[14]	林嘉意, 谢炬, 朱越平, 谢文玉. 代谢组学及其在环境毒理学中的应用[J]. 生物技术进展, 2022, 12(5): 683-689.
[15]	宋燚, 贾思雨, 武丽娜, 张伟, 欧晓娟, 黄坚. 遗传性胆红素代谢障碍与胆汁淤积NGS方法的建立及应用[J]. 生物技术进展, 2022, 12(4): 591-599.

白细胞介素-22在心血管疾病中的作用

Roles of Interleukin-22 in Cardiovascular Disease

RichHTML

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献 34

相关文章 15

编辑推荐

Metrics

本文评价